MDB Capital (NASDAQ:MDBH) Announces Earnings Results

MDB Capital (NASDAQ:MDBH) released its earnings results on Thursday. The company reported ($0.90) EPS for the quarter, FiscalAI reports. The firm had revenue of ($2.33) million for the quarter.

Here are the key takeaways from MDB Capital’s conference call:

• Microcap markets remain challenging: Management said small public and private companies are being neglected, and MDB’s planned expansion from one launch every 18 months to three to five launches annually is being deferred. Revenue is expected to remain lumpy as the company prioritizes a smaller number of high-conviction opportunities.
• MDB plans to operate more leanly without dilution: The company is targeting approximately $5 million–$6 million in annual operating expenses, expects portfolio companies to fund themselves as they mature, and said it is not seeking to raise additional capital at the MDB level.
• Public Ventures may generate near-term strategic value: MDB is in discussions with four or five potential partners regarding a partnership or sale of its clearing platform and aims to complete a transaction in the next quarter.
• PatentVest is pivoting toward an AI-enabled patent law firm: MDB plans to spin the business out as an independently financed entity, using AI and an alternative business structure to improve patent-prosecution efficiency and potentially attract legal talent and clients.
• Portfolio catalysts are approaching: eXoZymes is pursuing scalable manufacturing and commercial partnerships, while Paulex Bio is targeting an IPO in the fourth quarter and expects important diabetes-related clinical data in early 2027. Management characterized both assets as having substantial upside, though execution and financing risks remain.

MDB Capital Stock Down 2.5%

MDBH stock traded down $0.07 on Friday, reaching $2.94. 867 shares of the company’s stock were exchanged, compared to its average volume of 5,394. The stock has a fifty day moving average of $3.12 and a 200-day moving average of $3.25. MDB Capital has a twelve month low of $2.45 and a twelve month high of $4.80. The firm has a market cap of $30.33 million, a PE ratio of -1.39 and a beta of 1.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDB Capital in a research note on Thursday, July 2nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On MDB Capital

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. acquired a new position in shares of MDB Capital during the 2nd quarter worth $27,000. DRW Securities LLC acquired a new stake in shares of MDB Capital in the fourth quarter valued at about $40,000. Finally, Citadel Advisors LLC acquired a new stake in shares of MDB Capital in the third quarter valued at about $43,000. Institutional investors and hedge funds own 0.35% of the company’s stock.

MDB Capital Company Profile

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.